510(k) Report

PMA · Approved

Approved

Atellica IM free PSA II (fPSAII)

P250026PMAApproved May 11, 2026297-day reviewClass III

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Siemens Healthcare Diagnostics, Inc. · MTG Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions

Approved on May 11, 2026 through premarket approval, which rests on the device’s own clinical evidence after a 297-day review.

Decided
May 11, 2026
Review
297 days
Class
Class III
Product code
MTG
Recalls
None

PMA approvals rest on their own clinical evidence and do not claim a predicate, so this family tree starts here.

FIG. 1 — Lineage of P250026Source: FDA PMA database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA PMA database (decision fields and supplements), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MTG? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

Does it have a predicate?

PMA decisions do not claim a predicate device.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All MTG devices

MTG Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions: FDA decisions, review times, recalls and adverse event reports over 20 years. 2026, this device’s year, is highlighted.

FDA decisions per year · MTG

6in 2025

2007: 72008: 72009: 32010: 92011: 252012: 172013: 122014: 132015: 72016: 32017: 92018: 72019: 92020: 132021: 72022: 42023: 92024: 32025: 62026 (partial year): 6
2007high 25 (2011) · low 3 (2009)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MTG

Too few MTG 510(k)s in any year since 2007 to give a median.

Recalls per year · MTG

1in 2011

2008: 12011: 1
2007high 1 (2008) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · MTG

20in 2025

2011: 32012: 42013: 32014: 12015: 92016: 52017: 82018: 122019: 132020: 62021: 92022: 42023: 52024: 82025: 20
2007high 20 (2025) · low 0 (2007)2025

MAUDE reports naming product code MTG, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20077—00
20087—10
20093—00
20109—00
201125—13
201217—04
201312—03
201413—01
20157—09
20163—05
20179—08
20187—012
20199—013
202013—06
20217—09
20224—04
20239—05
20243—08
20256—020
20266—0—
Cite this page

510(k) Report. “P250026: Atellica IM free PSA II (fPSAII).” Lineage record from FDA PMA data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/P250026

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded Oct 30, 2026
  • Page last updated Nov 3, 2026